米妥昔单抗索拉夫坦辛联合卡铂治疗铂敏感复发性卵巢癌的1b期剂量递增研究的安全性与活性结果
该1b期剂量递增研究纳入18例铂敏感复发性上皮性卵巢癌或输卵管癌患者,肿瘤FRα阳性(≥25%细胞≥2+染色强度),接受米妥昔单抗索拉夫坦辛联合卡铂治疗。剂量从5mg/kg升至6mg/kg(调整理想体重),卡铂从AUC4升至AUC5。17例可评估患者确认客观缓解率为71%,中位无进展生存期15个月,不良事件多为轻度(≤2级)。
要点
- 米妥昔单抗索拉夫坦辛联合卡铂在铂敏感复发性卵巢癌中耐受良好且活性高。
- 17例可评估患者确认客观缓解率71%,含3例完全缓解和9例部分缓解。
- 中位无进展生存期15个月,中位缓解持续时间未达到。
核心结论
- 米妥昔单抗索拉夫坦辛联合卡铂是铂敏感复发性卵巢癌中耐受良好且高活性的方案。
- 作者认为该联合方案值得进一步随机化评估。
研究设计与样本
- 1b期剂量递增研究,纳入18例铂敏感复发性上皮性卵巢癌或输卵管癌患者。
- 入组要求肿瘤FRα阳性,即≥25%的细胞具有≥2+染色强度。
- 患者在第1天接受米妥昔单抗索拉夫坦辛和卡铂,21天为一周期(每3周一次)。
- 卡铂治疗结束后,研究者可酌情决定继续米妥昔单抗索拉夫坦辛维持治疗。
主要发现
- 18例患者入组并接受联合治疗,其中13例在卡铂停药后继续米妥昔单抗索拉夫坦辛维持治疗。
- 米妥昔单抗索拉夫坦辛剂量从5mg/kg递增至6mg/kg(调整理想体重),卡铂从AUC4递增至AUC5。
- 不良事件总体为轻度(≤2级),最常见的治疗中出现的不良事件为恶心、腹泻、血小板减少、视物模糊和疲乏。
- 17例可评估患者的确认客观缓解率为71%,包括3例完全缓解和9例部分缓解。
- 中位无进展生存期为15个月,中位缓解持续时间未达到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtansine when administered in combination with carboplatin to relapsed ovarian cancer patients. METHODS: Patients with recurrent, platinum-sensitive epithelial ovarian or fallopian tube cancer were enrolled. Eligibility included a minimum requirement of tumor FRα positivity (≥25% of cells with ≥2+ staining intensity). Patients received escalating doses of mirvetuximab soravtansine and carboplatin on day 1 of a 21-day cycle (once every 3 weeks). Mirvetuximab soravtansine maintenance therapy was permitted, at the investigators discretion, following cessation of carboplatin treatment. Adverse events, tumor response, and progression-free survival (PFS) were determined. RESULTS: Eighteen patients were enrolled and dosed with combination therapy; thirteen continued with mirvetuximab soravtansine maintenance following carboplatin discontinuation. Mirvetuximab soravtansine dosing was escalated from 5 to 6 mg/kg (adjusted ideal body weight) and carboplatin from AUC4 to AUC5. Adverse events were generally mild (≤ grade 2) with nausea, diarrhea, thrombocytopenia, blurred vision, and fatigue being the most common treatment-emergent toxicities. For all evaluable patients (n = 17), the confirmed objective response rate (ORR) was 71%, including three complete responses and nine partial responses, and the median PFS was 15 months. A median duration of response was not reached. CONCLUSION: These data demonstrate that mirvetuximab soravtansine combined with carboplatin is a well-tolerated and highly active regimen in recurrent, platinum-sensitive ovarian cancer. Further evaluation of this combination in a randomized fashion is warranted.
引用
- Moore KN, O'Malley DM, Vergote I, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018. PMID: 30093227. doi:10.1016/j.ygyno.2018.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。